ALOE - ALOE VERA - Oral

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient.

Notes

Date

July 31, 2018

Proper name(s), Common name(s), Source material(s)

Table 1.Proper name(s), Common name(s), Source material(s)
Proper name(s) Common name(s) Source material(s)
Proper name(s) Part(s)
Aloe Vera
  • Aloe
  • Aloe vera
  • Barbados aloe
  • Curaçao aloe
  • True aloe
  • West Indian aloe
Aloe Vera Leaf Latex

References: Proper name: USDA 2018; Common names: USDA 2018, McGuffin et al. 2000; Source material: Barnes et al. 2007, Williamson 2003.

Route(s) of administration

Oral

Dosage form(s)

This monograph excludes foods or food-like dosage forms as indicated in the Compendium of Monographs Guidance Document.

Acceptable dosage forms for the age category listed in this monograph and specified route of administration are indicated in the Compendium of Monographs Guidance Document.

Use(s) or Purpose(s)

The following combined use(s) or purpose(s) is/are also acceptable:

(Used in Herbal Medicine as a) stimulant laxative for short-term relief of occasional constipation (EMEA 2006).

Notes

Claims for traditional use must include the term "Herbal Medicine", "Traditional Chinese Medicine" or "Ayurveda".

Dose(s)

Subpopulation(s)

Adolescents 12 to 17 years and adults 18 years and older (EMEA 2006; Brinker 2001).

Quantity(ies)

Methods of preparation: Dry, Powder, Non-Standardized(Dry extract, Tincture, Fluid extract, Decoction, Infusion)

50 - 300 milliliters dried leaf latex, per day (Williamson 2003; Bradley 1992)

Methods of preparation: Standardized extracts(Dry extract, Tincture, Fluid extract, Decoction, Infusion)

10 - 30 milligrams hydroxyanthracene derivatives (calculated as barbaloin/aloin), per day (Barnes st al, 2007; EMEA 2006; Blumenthal et al. 1998)

Direction(s) for use

Optional(for products which provide a dosage range):

The correct individual dose is the smallest one required to produce a soft-formed stool (EMEA 2006).

Duration of use

Consult a health care practitioner/health care provider/health care professional/doctor/physician for use beyond 7 days (EMEA 2006; Brinker 2001).

Risk information

Caution(s) and warning(s)

Contraindication(s)

Known adverse reaction(s)

Stop use if hypersensitivity/allergy occurs (Brinker 2018; EMEA 2006).

Non-medicinal ingredients

Must be chosen from the current Natural Health Products Ingredients Database (NHPID) and must meet the limitations outlined in the database.

Storage conditions

No statement required.

Specifications

References cited

References reviewed